LabConnect and The Bracken Group Forge Strategic Partnership to Enhance Radiopharmaceutical Trial Support
LabConnect's collaboration with The Bracken Group addresses the growing demand for specialized radiopharmaceutical expertise in clinical trials, positioning the partnership to better serve biotech and pharmaceutical companies developing targeted treatments and diagnostics.
LabConnect, a leading provider of global central laboratory and support services for clinical trials, has announced a strategic collaboration with The Bracken Group to enhance its radiopharmaceutical support capabilities. This partnership comes at a critical time as demand for radiopharmaceutical expertise continues to surge, with industry growth estimated between 15% and 20% annually. The collaboration positions LabConnect to better serve biotech and pharmaceutical clients advancing targeted treatments and diagnostics in this rapidly expanding field.
The Bracken Group brings significant scientific leadership and strategic expertise to the partnership, with recognized key opinion leadership and a broad scientific approach across development, regulatory, and commercialization efforts. Wes Wheeler, CEO at LabConnect, emphasized the strategic importance of the collaboration, stating that it creates a unique opportunity to integrate operational excellence with deep scientific acumen. The partnership strengthens LabConnect's ability to support global clients with the complex logistical and analytical challenges specific to radiopharmaceutical trials.
Colin Miller, PhD, CEO at Bracken Consulting, highlighted the alignment between the two organizations, noting that LabConnect's commitment to innovation matches Bracken's mission. Miller described the partnership as creating a bridge between medicine, science, and operations that is unmatched in the industry. He further explained that Bracken's position as the global leader in consulting for radiopharmaceutical development from pre-clinical to market strategy, combined with LabConnect's capabilities, establishes the partnership as the go-to organization for clients developing both diagnostics and radiolabeled therapy (RLT) products.
The collaboration will focus on enhanced service delivery in critical areas such as sample processing, logistics, and scientific oversight. These components are particularly important in the highly regulated radiopharmaceutical field, where specialized handling and expertise are required. The partnership addresses the growing need for comprehensive support services as more companies invest in radiopharmaceutical development. Additional information about LabConnect's services can be found at https://www.labconnect.com, while details about The Bracken Group's consulting offerings are available at https://www.thebrackengroup.com.
This strategic alliance represents a significant development in the clinical trial support landscape, particularly for the radiopharmaceutical sector that has been experiencing substantial growth. The combination of LabConnect's operational capabilities with Bracken's scientific expertise creates a comprehensive solution for companies navigating the complexities of radiopharmaceutical development. The partnership comes at a time when the industry faces increasing demands for specialized support services capable of handling the unique requirements of radioactive compounds used in both diagnostic and therapeutic applications.